nausea decreases with ongoing usage a steady weight loss occurs in some patients over 2 years (may be related to nausea & CNS-mediated loss of appetite) there is an increased risk of hypoglycemia when exenatide is used with a sulfonylurea The dose of the sulfonylurea may need to be reduced if hypoglycemia occurs when combined with exenatide Most serious : rare & sometimes fatal necrotizing or hemorrhagic pancreatitis When initiating patients on Byetta, watch for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting)
This physical fullness provides a mechanical signal to stop eating sooner during meals
This indicates there is some other benefit of semaglutide, as it helped even if there was no weight loss (a common finding in many studies of semaglutide) A study chose patients with known moderate to severe sleep apnea who wouldnt use CPAP
It showed about 15% weight loss in trials, with very promising results for reducing liver fat in people with fatty liver disease
Calculate your dose and schedule Map the trial titration protocol onto a calendar: enter a start date and a target dose level to see the week-by-week escalation, the units to draw at each step, and what to expect and watch for along the way
Other serious but less common risks include pancreatitis, gallbladder problems, kidney issues, and hypoglycemia when used with certain other diabetes medications